SUDA Pharmaceuticals Ltd. announced preliminary results from a pharmacokinetic study evaluating novel mouth spray formulations of anagrelide. The study involved comparing three different mouth spray formulations against the current commercial capsule in a canine model. The work has been conducted by the leading contract research organisation, Covance Inc., based in Harrogate, England. The Company will update the market with the results when the report has been finalised. The preliminary results from the crossover study using five animals suggest that one of the formulations was able to increase the bioavailability of anagrelide while reducing exposure to a cardio stimulatory metabolite. This supports SUDA's hypothesis that such a formulation could be more safely administered to cancer patients, potentially resulting in fewer cardiovascular side-effects.